|
16.07.25 - 07:24
|
Imugene Raises $37.5m to Advance Azer-Cel Clinical Trials for Refractory Lymphoma Patients (Small Caps)
|
|
Imugene (ASX: IMU) has received firm commitments for a $37.5 million capital raising to advance the development of off-the-shelf (allogeneic) CAR-T drug azer-cel for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company will raise an initial $22.5 million from the placement of 68.2 million shares priced at $0.33 each, a 22.4% discount to […]
The post Imugene Raises $37.5m to Advance Azer-Cel Clinical Trials for Refractory Lymphoma Patients appeared first on Small Caps....
|
|
|
|
|
|
|
|
|
02.07.25 - 08:57
|
XFRA: ILA: Aussetzung/Suspension (XETRA)
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
IMUGENE LTD. ILA AU000000IMU9 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
|
|